Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. reports the results of the Annual General Meeting of Shareholders held on April 28, 2022. The meeting addressed governance matters, including the approval of statutory accounts for the fiscal year ended December 31, 2021, and the re-appointment of the Board of Directors.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. It confirms only that shareholders approved the adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2021.
Material Changes
No material financial changes or operational updates are detailed in this document. The primary content consists of shareholder voting outcomes regarding corporate governance and director appointments.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The document is strictly a record of shareholder resolutions.
Key Facts for Investor Verification
- Shareholders approved the Dutch statutory annual accounts for the fiscal year ended December 31, 2021.
- Ernst & Young Accountants LLP was instructed to perform the external audit for the 2022 financial year.
- Directors Prof. Niels Riedemann and Prof. Renfeng Guo were re-appointed as executive directors.
- Directors Mr. Nicolas Fulpius and Mr. Richard Brudnick were re-appointed as non-executive directors.
- The Board received extended authorization to issue shares, limit pre-emption rights, and acquire company shares.